Belatacept is a biologic drug used for the prevention of transplant rejection in adults receiving a kidney transplant. Marketed as Nulojix, it produces immunosuppression by blocking a costimulatory signal required for the activation of many T cells. It is administered by intravenous infusion as part of a multidrug transplant regimen. Its use is restricted to recipients with evidence of previous Epstein–Barr virus (EBV) infection because of the increased risk of post-transplant lymphoproliferative disorder in recipients without established EBV immunity.
Structure and mechanism
Belatacept is a fusion protein comprising the modified extracellular portion of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to the Fc portion of human immunoglobulin G1. It is closely related to abatacept, but contains two amino-acid substitutions that increase its binding affinity for the costimulatory molecules CD80 and CD86. Although it contains part of an antibody, it is not a conventional monoclonal antibody.
T-cell activation ordinarily involves recognition of an antigen together with additional signals. One important costimulatory signal occurs when CD28 on a T cell binds CD80 or CD86 on an antigen-presenting cell. Belatacept binds CD80 and CD86, preventing their interaction with CD28. This reduces T-cell activation and the immune response against a transplanted organ.
Its mechanism differs from that of a calcineurin inhibitor, such as cyclosporine or tacrolimus, which interferes with intracellular signaling after T-cell activation. Belatacept does not directly inhibit calcineurin and avoids the characteristic kidney toxicity associated with that drug class. However, costimulation blockade does not suppress every pathway capable of producing rejection, and acute rejection can still occur.
Clinical use and administration
Belatacept received initial regulatory approval in the United States and European Union in 2011 for prevention of rejection following adult kidney transplantation.
The approved treatment framework combines belatacept with other immunosuppressive agents, including induction therapy with an interleukin-2 receptor antagonist, mycophenolic acid, and corticosteroids. It is not intended to function as a stand-alone treatment.
Infusions are given more frequently during the early post-transplant period, followed by maintenance infusions generally every four weeks. Unlike oral maintenance drugs, belatacept requires regular attendance for intravenous administration.
The United States prescribing information limits use to EBV-seropositive recipients; EBV-negative recipients and those whose EBV status is unknown are excluded. Its efficacy and safety are not established for transplant recipients younger than 18 years. Use in liver transplantation is not recommended because a clinical trial found increased graft loss and death.
Belatacept has also been studied as a replacement for calcineurin inhibitors in kidney recipients already receiving maintenance immunosuppression. Such conversion is a distinct clinical setting, with potential improvements in kidney function balanced against rejection risk.
Evidence and comparative outcomes
The pivotal BENEFIT and BENEFIT-EXT randomized controlled trials compared belatacept-based regimens with cyclosporine-based regimens in different kidney donor populations.
These studies demonstrated better kidney function with belatacept, assessed using measures including estimated glomerular filtration rate. However, belatacept was associated with more early acute rejection in important trial comparisons. Thus, better measured kidney function did not mean that rejection occurred less often.
Long-term follow-up of BENEFIT, which enrolled recipients of living-donor or standard-criteria deceased-donor kidneys, found a lower risk of death or graft loss with belatacept than with cyclosporine. A comparable survival advantage was not established in BENEFIT-EXT, which involved extended-criteria deceased-donor kidneys.
The principal comparator in these pivotal trials was cyclosporine. Their results therefore do not establish equivalent advantages over tacrolimus, another widely used maintenance immunosuppressant.
Adverse effects and limitations
The major safety concerns arise from suppression of the immune system.
Post-transplant lymphoproliferative disorder. Belatacept carries a boxed warning in the United States for post-transplant lymphoproliferative disorder (PTLD), including cases involving the central nervous system. PTLD encompasses abnormal lymphoid proliferations, including forms of lymphoma. The risk is particularly elevated in EBV-seronegative recipients.
Serious infections. Treatment increases susceptibility to serious bacterial, viral, fungal, and opportunistic infections. Reported concerns include tuberculosis, BK virus-associated kidney disease, and progressive multifocal leukoencephalopathy, a rare JC virus-associated brain infection.
Malignancy and other adverse events. Immunosuppression increases the risk of certain malignancies, including skin cancer. Commonly reported adverse events in kidney transplant trials included anemia, diarrhea, urinary tract infection, peripheral edema, and hypertension. Infusion-related reactions and hypersensitivity reactions can also occur.
Belatacept’s principal clinical trade-off is avoidance of calcineurin-inhibitor-associated kidney toxicity at the cost of intravenous administration, specific eligibility restrictions, and a different pattern of rejection and infection risks. Outcomes depend on the accompanying immunosuppressive regimen, recipient characteristics, and transplant setting.